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Abstract
The receptor tyrosine kinase (RTK) ROR1 is overexpressed and of importance for the survival of various malignancies,
including lung adenocarcinoma, breast cancer and chronic lymphocytic leukemia (CLL). There is limited information
however on ROR1 in melanoma. In the present study we analysed in seven melanoma cell lines ROR1 expression and
phosphorylation as well as the effects of anti-ROR1 monoclonal antibodies (mAbs) and ROR1 suppressing siRNA on cell
survival. ROR1 was overexpressed at the protein level to a varying degree and phosphorylated at tyrosine and serine
residues. Three of our four self-produced anti-ROR1 mAbs (clones 3H9, 5F1 and 1A8) induced a significant direct apoptosis
of the ESTDAB049, ESTDAB112, DFW and A375 cell lines as well as cell death in complement dependent cytotoxicity (CDC)
and antibody dependent cellular cytotoxicity (ADCC). The ESTDAB081 and 094 cell lines respectively were resistant to direct
apoptosis of the four anti-ROR1 mAbs alone but not in CDC or ADCC. ROR1 siRNA transfection induced downregulation of
ROR1 expression both at mRNA and protein levels proceeded by apoptosis of the melanoma cells (ESTDAB049, ESTDAB112,
DFW and A375) including ESTDAB081, which was resistant to the direct apoptotic effect of the mAbs. The results indicate
that ROR1 may play a role in the survival of melanoma cells. The surface expression of ROR1 on melanoma cells may support
the notion that ROR1 might be a suitable target for mAb therapy.
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Introduction
Melanoma is a skin cancer arising from melanocytes located in
the epidermis. The incidence of melanoma is rapidly increasing.
The frequency of melanoma is only 4% of all dermatological
cancers but responsible for 80% of the mortality in skin cancer.
Early detection and treatment may improve prognosis [1]. A series
of melanoma-associated antigens (MAGE) has been identified on
melanoma cells [2–4]. Large efforts have been done to use
different MAGEs for immunotherapy of melanoma patients, but
most clinical trials have failed [5].
Receptor tyrosine kinases (RTKs) are important structures
involved in cell signaling, differentiation and proliferation of
normal and malignant cells [6]. RTKs and their signaling
pathways may contribute to the dysregulation of malignant cells,
as self-sufficiency for growth factors, evasion from apoptosis,
unlimited cell replication and metastasis [7]. The receptor
tyrosine-kinase-like orphan receptor 1 (ROR1) is a member of
the RTK families [8–11] and a highly conserved receptor with no
clearly identified ligand/s [12]. Wnt5a has however been
suggested as a candidate ligand for ROR1 [9,13–14].
ROR1 is a transmembrane protein consisting of 937 amino acid
residues with an extra and intracellular part. The extracellular part
consists of 3 regions, including the Ig-like, cysteine rich (CRD) and
kringle (KNG) domains. The CRD and KNG domains might be
ligand binding sites [13,15]. The intracellular part contains a
tyrosine kinase domain that might be triggered to phosphorylation
by other cytoplasmic signaling proteins [16]. ROR1 is expressed
during the development of the nervous system and regulates
survival and maintenance of neural progenitor cells in the brain
[14]. It is also expressed in other organs during embryogenesis and
of importance for the morphogenesis of several organs [12].
The role of ROR1 in various malignancies is not well
understood. No mutations have been noted [17]. ROR1 is
however considered to be a survival factor for various malignan-
cies including chronic lymphocytic leukemia (CLL) [18], breast
cancer [13] and lung adenocarcinoma [15]. ROR1 might be a
promising antigen to be targeted. Anti-ROR1 monoclonal
antibodies (mAbs) and ROR1 specific siRNAs have been shown
to induce apoptosis and necrosis of malignant cells [16,19–20].
In the current study, we analysed the expression and
phosphorylation of ROR1 in a series of malignant melanoma cell
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lines using RT-PCR, immunocytofluorescence (IF), flow cytometry
and western blot. The cytotoxic effects of anti-ROR1 mAbs were
evaluated in the absence or presence of complement (complement
dependent cytotoxicity) (CDC) or immune effector cells (antibody
dependent cell-mediated cytotoxicity) (ADCC) and ROR1 siRNA
was used for gene silencing.
Materials and Methods
Cell lines and controls
The melanoma cell lines ESTDAB049, 075, 081, 094 and 112
were obtained from the European Searchable Tumor Cell Line
Data Base (ESTDAB project, contract no. QLRI-CT-2001-
01325) [21]. The DFW melanoma cell line was derived from a
metastatic lesion from a patient at Radiumhemmet, Karolinska
Hospital University Solna, Stockholm, Sweden [22]. A375
(melanoma cell line) and T47D (human ductal breast epithelial
tumor cell line) were obtained from American Type Culture
Collection (ATCC). After thawing, cells were grown in RPMI-
1640 (Gibco, Life Technologies, Karlsruhe, Germany) containing
10% FCS (Gibco), 2% glutamine (Biochrom KG, Berlin,
Germany) and 100 ug/ml penicillin/streptomycin (Biochrom
KG) (complete medium) at 37uC in a humidified incubator with
5% CO2.
Production of anti-ROR1 monoclonal antibodies
Mouse monoclonal antibodies against ROR1 were generated
against the extracellular part of ROR1 as previously described
[20]. Out of more than 20 clones, four clones including 1A8, 1E9,
5F1 and 3H9 (all of the IgG1 isotype) were selected. The
characterization and specificity of the anti-ROR1 mAbs (Avicenna
Research Center, Tehran, Iran) were checked by ELISA and after
transfection of the HEK293 cell line with the extracellular domain
of ROR1 in western blot as previously described [17].
RNA preparation, cDNA synthesis and RT-PCR
Total RNA was purified from cells, using pure link RNA mini-
kits (Ambion, Inc., Austin, Texas, USA). One ug of high quality
RNA was reversely transcribed using a first strand cDNA synthesis
kit (Fermentas, St. Leon-Rot, Germany) according to the
manufacturer’s instructions. PCR amplification was performed
as previously described [23], using 150 ng of cDNA for PCR
amplification. ROR1 specific primers, 59-CTGCTGCCCAA-
GAAACAGAG-39 (position 455–474) as the sense and 59-
CATAGTGAAGGCAGCTGTGATCT-39 (position 977–999) as
antisense primers, with a PCR product of 545 bp (reference: g.b.
M97675) were used for ROR1 amplification [17]. Beta-actin was




Cells were grown on coverslips (Marienfeld GmbH & Co,
Lauda-Ko¨nigshofen, Germany) placed in 35-mm dishes in an
incubator with humidified air and 5% CO2 at 37uC. After 24 h of
incubation, medium was removed. Cells were dried at room
temperature (RT) and fixed with cold neutral buffered formalin for
5 min. The slides were washed with tris-buffered saline (pH=7.4),
containing 0.1% Bovine Serum Albumin (TBS-BSA) and blocked
with 5% sheep serum diluted in TBS-BSA for 30 min. Slides were
then incubated with 5 ug/ml of ROR1 mAbs as well as with a
non-relevant mAb (mouse IgG1 isotype) (eBioscience, Inc., San
Diego, California, USA) for 1 h at RT. Following three washes,
slides were incubated with FITC- conjugated sheep anti-mouse
IgG (1:100) (Avicenna Research Center) for 1 h. After three
washes in TBS-BSA, the nuclei were counterstained with 1 ug/ml
of 49, 6-Diamidino-2-Phenylindole Dihydrochloride (DAPI) (Sig-
ma-Aldrich Corp., Saint Louis, MO) for 5 min. Finally, cells were
mounted in PBS-glycerol 50% and examined with a fluorescent
microscope (Zeiss Axioplan2, Oberkochen, Germany).
Flow cytometry analysis
Surface staining of cells was performed as previously described
[24]. Briefly, 106 cells were washed in PBS and suspended in
100 ul of FACS buffer (PBS, 0.1% sodium azide, and 0.5% BSA).
Five ug/ml of the respective anti-ROR1 mAbs or one ug/ml of
polyclonal goat anti-ROR1 antibody (R&D system, Minneapolis,
MN, USA) was added to the cells and incubated at 4uC for 1 h.
Cells were washed with FACS buffer and FITC conjugated sheep
anti-mouse Ig or FITC conjugated rabbit anti-goat Ig (Dako,
Glostrup, Denmark) (1:100) were added and incubated at 4uC for
1 h. Finally, cells were washed with FACS buffer and fixed with
1% paraformaldehyde in PBS. A FACSCalibur flow cytometer
(BD Bioscience, Mountain View, CA, USA) was used to analyse
ROR1 expressing cells. 56104 events were counted. Cells were
analyzed using the FlowJo software program (Tree Star Inc.
Ashland OR, USA).
Western blot analysis
106106 cells were lysed in 200 ul of lysis buffer [0.1% SDS, 1%
Triton X-100, 50 mM Tris- HC1, pH 7.4, 150 mM NaCl, 5 mM
EDTA, 1% protease inhibitor cocktail (Sigma-Aldrich) and
phosphatase inhibitor (Roche, Stockholm, Sweden)] and incubat-
ed on ice for 30 min with 5 min interval and vortexed for 10 sec.
Bicinchoninic acid (BCA) protein assay kit (Thermo Scientific, IL,
USA) was used to measure the protein concentration according to
the manufacturer’s instructions. Ten ug of the cell lysate or
immunoprecipitated ROR1 (using goat anti-ROR1 antibody) was
run on 10% Bis-Tris SDS-PAGE gel at 120V/90mA for 2 h (IP-
WB). After electrophoresis, proteins were transferred to PVDF
membrane (Millipore Corporation, Bedford, MA, USA) and
blocked overnight at 4uC with 5% nonfat dry milk (skim milk) or
BSA in TBS containing 0.1% Tween 20 (TBS-T). Filters were
incubated with anti-phospho-tyrosine (0.5 ug/ml) (PY99, Santa
Cruz Biotechnology, Inc., CA, USA), anti-phospho-serine mAbs
(clone 4A4) (0.5 ug/ml) (Millipore Corporation) or goat anti-
ROR1 polyclonal antibody (R&D system) (0.2 ug/ml) for 1 h at
RT. After washing with TBS-T, filters were incubated with
peroxidase-conjugated rabbit anti-goat or rabbit anti-mouse
immunoglobulin (Dako) for 1 h at RT followed by washings and
developed using the advanced ECL chemiluminescence detection
system (GE Healthcare, Uppsala, Sweden).
Cleaved PARP as well as caspase-8 and 9 and MCL-1
expression were analyzed using cell lysates from the apoptosis
experiments (see below). Briefly, 10 ug of the protein lysate was
run in western blot. Filters were incubated with rabbit anti-PARP,
cleaved caspase-8 (p 43/41 and p18), cleaved caspase-9 (p37) and
MCL-1 antibodies (Cell Signaling Technology, Danvers, MA,
USA) respectively overnight at 4uC, and subsequently with a
peroxidase-conjugated goat anti-rabbit antibody (Dako). Finally,
blots were developed with a chemiluminescence detection system
[20].
Annexin-V/PI apoptosis assay
56104 cells/well were cultured in 6 replicates in 24 well plates.
After 24 h, medium was replaced and cells were incubated with
5 ug/ml of the ROR1 mAbs in 1 ml of complete medium. Cells
treated with a non-relevant isotype control mAb (mouse IgG1
ROR1 Inhibition in Melanoma
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isotype) (eBioscience) or 1 uM staurosporine (Sigma-Aldrich) were
used as controls, respectively. After 24 h of incubation at 37uC in
humidified air with 5% CO2, cells were collected (24 well plates
were incubated on ice for 10 min and then cells were suspended
by pipetting), washed twice with PBS and resuspended in 150 ul of
binding buffer. Five ul of FITC-conjugated Annexin-V and PI
(propidium Iodide) (BD Biosciences) was added to the cells,
vortexed and incubated at RT in the dark for 10 min. Apoptosis
was measured by flow cytometry (FACSCalibur, BD Biosciences).
Cells were analyzed using the FlowJo software program.
XTT cytotoxicity assay
XTT (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazoli-
um-5-carboxanilide) cytotoxicity assay was used as previously
described [25]. Briefly, 104 cells were incubated in 200 ul
complete medium in 6 replicates using 96 well plates. After
24 h, medium was replaced and anti-ROR1 mAbs were added to
the cells (5 ug/ml) as well as the non-relevant isotype control mAb
(mouse IgG1 isotype). The T47D cell line treated with mAbs was
used as a negative control [16]. Cells were incubated for 24 h with
mAbs and 20 ul of XTT (5 mg/ml) (Sigma-Aldrich) in PBS was
added after activation of XTT with PMS (N-methyl dibenzopyr-
azine methyl sulfate) (Sigma-Aldrich). Cells were incubated for
further 2 h at RT. Optical density (OD) was measured at 450 nm.
Cytotoxicity was calculated as follows: % cytotoxicity = (Test OD -
background OD)/(positive control OD - background OD)6100.
The positive control OD was defined as the value of untreated cells
at time zero and background OD as the value of medium alone.
CDC and ADCC assays
The effect of anti-ROR1 mAbs in CDC was evaluated as
previously described [26]. Briefly, 56104 target cells were plated in
V-bottomed microtiter plates (Nunc, Roskilde, Denmark) in
100 ul complete medium. Cells were incubated with 5 ug/ml of
each of the anti-ROR1 mAb as well as with 5 ug/ml of the non-
relevant isotype control mAb (mouse IgG1 isotype) for 30 min at
RT followed by washings with RPMI-1640. Twenty percent fresh
normal human serum (NHS) in 100 ul complete medium was
added and cells incubated at 37uC in a humidified air with 5%
CO2 for 2 h. Finally, cells were collected, washed twice with PBS
and resuspended in 150 ul of Annexin-V/PI binding buffer. Five
ul of PI was added to the cells, vortexed and incubated at RT in
the dark for 10 min. The frequency of PI stained cells was
measured by flow cytometry.
ADCC assay was performed as previously described [20].
Briefly, cells were labeled with 2.8 MBq sodium Cr51 (PerkinEl-
mer Inc. Wellesley, MA, USA) for 3 h at 37uC. After 3 washes
with RPMI-1640, 104 cells in 100 ul medium were added to each
round-bottomed microtiter well (Nunc) and natural killer (NK)
cells enriched from healthy donors buffy coat [26] were added to
yield target: effector cell ratios of 1:25 and 1:50 to a final volume of
200 ul containing 5 ug/ml of the anti-ROR1 mAbs or the non-
relevant isotype control mAb (mouse IgG1 isotype). Each
experiment was run in six wells. After 4 h at 37uC, the reaction
was stopped by centrifugation. Cr51 release was measured by a
gamma counter (Beckman Gamma 5500, Beckman Coulter,
Fullerton, CA). The percentage of target cell lysis was calculated
based on the following formula: % specific lysis = (experiment
cpm- spontaneous cpm)/(maximum cpm-spontaneous cpm)6100.
Maximum Cr51 release was determined by adding 1% of Triton
X-100 to the target cells and spontaneous release was measured in
the absence of antibodies and effector cells.
ROR1 siRNA transfection
Downregulation of endogenous ROR1 mRNA was performed
as previously described [19]. The siRNA sequences used to target
59-ATGAACCAATGAATAACATC-39 ROR1 mRNA with an-
tisense 59-GAUGUUAUUCAUUGGUUCAdTdT-39 and sense
59-UGAACCAAUGAAUAACAUCdTdT-39 sequences. Control
siRNA (MISSION siRNA Universal Negative Control; Sigma-
Aldrich) was used as a negative control. Cells were harvested after
6, 12, 24 and 36 h of incubation for mRNA preparation, the
Annexin-V/PI apoptosis assay and for western blot.
Data analysis
Statistical analyses were performed using student’s t-test and
Mann–Whitney U test as appropriate. Analyses were conducted
using the SPSS statistical package (SPSS, Chicago, IL). P-values
less than 0.05 were considered to be significant.
Results
ESTDAB (European Searchable Tumor Cell Line Database)
contains more than 100 melanoma cell lines with defined HLA
class I and II genotypes in the ESTDAB Melanoma Cell Bank
(Tubingen, Germany). These cell lines also have been character-
ized for glycan composition in relation to clinical tumor
progression [21,27–29]. In the current study, we randomly
selected five cell lines (049, 075, 081, 094 and 112) from this
collection and two other melanoma cell lines (A375 and DFW).
ROR1 expression and phosphorylation
The expression of ROR1 mRNA was determined by RT-PCR.
ROR1 was expressed in all melanoma cells at the mRNA level but
not in the T47D cell line. The protein expression of ROR1 was
assessed by IF. All melanoma cell lines expressed the ROR1
molecule (anti-ROR1 mAb clone 3H9). Representative results for
the ESTDAB112 cells are shown in Figure 1A. In IP-WB
(immunoprecipitation followed by western blot), a 130 kDa band
representing fully glycosylated ROR1 was detected using a goat
anti-ROR1 polyclonal antibody for immunoprecipitation. This
band could also be shown to be phosphorylated using anti-
phospho-tyrosine and phospho-serine mAbs. No expression of
ROR1 was seen in the T47D cell line [16] (Fig. 1B).
ROR1 surface expression and intensity was also analysed by
flow cytometry. All cell lines expressed ROR1 as detected by the
four anti-ROR1 mAbs and a polyclonal goat anti-ROR1 antibody
(Table 1). However it should be noted that a proportion (about
50%) of the melanoma cells did not express ROR1.
Induction of apoptosis by anti-ROR1 mAbs
Induction of apoptosis by the anti-ROR1 mAbs in the absence
of complement or effector cells was analysed after 24 h incubation
(Fig. 2). The frequency of apoptotic/necrotic cells (lower right,
upper left and right quadrants) induced by a non-relevant isotype
control mAb (mouse IgG1 isotype) was deducted from the
frequency of cells treated with the anti-ROR1 mAbs. Anti-
ROR1 mAbs alone induced apoptosis of melanoma cells varying
between 4% and 54% as determined by Annexin-V/PI staining
(Fig. 2A) and the XTT assay (Fig. 2B). Representative experiments
are shown in Figure 2C. Different anti-ROR1 mAbs had various
effects on the individual cell lines. The anti-ROR1 mAb clones
5F1, 3H9 and 1A8 were the most effective using ESTDAB049,
ESTDAB112, DFW and A375 cell lines, while anti-ROR1 mAb
clone 1E9 was the most effective using ESTDAB075 cells.
ESTDAB081 and 094 cell lines were resistant to the direct
cytotoxic effects of the anti-ROR1 mAbs. The frequency of ROR1
ROR1 Inhibition in Melanoma
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positive cells did not differ significantly comparing the various
melanoma cell lines. No effect on apoptosis of the non-relevant
isotype control mAb (mouse IgG1 isotype) was observed. The anti-
ROR1 mAbs did not induce apoptosis of the ROR1 negative cell
line T47D.
Western blot analyses for cleaved PARP and caspase-8/9 as well
as downregulation of MCL-1 were done using protein lysates
prepared from the 24 h apoptosis experiments. The effects of the
anti-ROR1 mAb clone 5F1 were tested on the ESTDAB049,
ESTDAB112 and A375 melanoma cells. The anti-ROR1 mAbs
induced cleavage of PARP, caspase 8 and caspase 9 as well as
down-regulation of MCL-1 (Fig. 2D).
Staurosporine was used as a positive control for apoptosis
induction. More than 70% of cells had gone into apoptosis after
24 h incubation (data not shown). Staurosporine also induced a
significant PARP, caspase 8 and 9 cleavage as well as MCL-1
downregulation (Fig. 2D).
Cytotoxic effects of anti-ROR1 mAbs in CDC
The effect of anti-ROR1 mAbs in CDC was evaluated after 2 h
incubation of cells in the presence of human complement. Anti-
ROR1 mAbs could activate complement to lyse melanoma cells to
a varying degree. The CDC activity of the various mAbs against
the different cell lines are shown in Figure 3A–C. The anti-ROR1
mAb clone 1E9 had the lowest CDC activity against the A375 cell
line. Lysis of all mAbs in the presence of complement using the 7
melanoma cell lines (except for anti-ROR1 mAb clone 1E9 on
A375 cell line) was statistically significant compared to no
complement (p,0.01). No CDC activity was seen using the
ROR1 negative T47D cell line (Fig. 3C). Comparison of 4 mAbs
in CDC showed a significantly better effect of mAb 5F1 compared
to 3H9 using ESTDA049 (p= 0.01), of 3H9 on the ESTDAB075
cell line compared to the other 3 mAbs (p= 0.01-0.001), of mAb
3H9 compared to 5F1 on ESTDAB094 (p = 0.01) and of mAbs
Figure 1. Protein expression of the receptor tyrosine kinase ROR1 in melanoma cell lines. Representative experiment (IF) showing the
expression of ROR1 on the ESTDAB112 cell line using the anti-ROR1 (clone 3H9) mAb (406). Nuclei were counterstained with DAPI (blue). A non-
relevant isotype control mAb (mouse IgG1 isotype) was used as a negative control (A). Western blot analysis of ROR1 protein expression and
phosphorylation in melanoma cells detected by a goat anti-ROR1 antibody, anti-p-tyrosine (PY99) and anti-p-serine (clone 4A4) mAbs (B). ROR1
protein was shown to be phosphorylated in all cell lines using immunoprecipitation of ROR1. A 130 kDa band corresponding to the fully
glycosylated/phosphorylated ROR1 was observed. The T47D cell line was used as a ROR1 negative control [16].
doi:10.1371/journal.pone.0061167.g001
Table 1. Frequency of ROR1 positive melanoma cells.
ROR1 mAb ESTDAB
049 075 081 094 112 DFW A375 T47D
1A8 60 (17.1) 52.5 (16) 60 (60.3) 59.1 (54.5) 52.3 (19.7) 59.4 (52.1) 57.9 (36.7) 5 (3)
1E9 64.3 (27) 53.6 (14) 63.5 (38.6) 75.2 (113) 58.6 (23) 65 (74) 44 (12.5) 11 (4)
5F1 68.9 (29.3) 59.3 (22.3) 62.5 (40.4) 70.9 (46.6) 56.8 (15.8) 68.3 (47.5) 71.3 (86.4) 9 (5)
3H9 78.1 (99.6) 58.4 (22.2) 70 (74.2) 70.4 (46.7) 63.7 (24.1) 62.4 (85.7) 58.7 (56.9) 5 (3)
Frequency (%) of ROR1 positive cell lines and Geometric Mean Fluorescence Intensity, stained by 4 anti-ROR1 mAbs in flow cytometry.
doi:10.1371/journal.pone.0061167.t001
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Figure 2. Induction of apoptosis in melanoma cells using anti-ROR1 mAbs. Frequency (%) of apoptotic/necrotic cells in Annexin-V+/PI+ (A)
and XTT cytotoxicity assay (B) induced by anti-ROR1 mAbs in the absence of complement or immune effector cells [anti-ROR1 mAb clones 1A8 (%),
1E9 ( ) and 5F1 ( )3H9 (&)]. Dot plot diagrams of apoptosis induced by anti-ROR1 mAbs (clones 1A8 and 3H9) in melanoma cells and ROR1 negative
ROR1 Inhibition in Melanoma
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1A8, 5F1 and 3H9 compared to 1E9 mAb on the A375 cell line
(p = 0.01-0.0001).
Antibody dependent cell-mediated cytotoxicity (ADCC)
Purified NK cells were used as effector cells. Various effects of
the anti-ROR1 mAbs were noted (Fig. 4). The lowest and highest
cytotoxic activity was observed for the anti-ROR1 mAb clone 5F1
on DFW (Fig. 4A) and ESTDAB081 (Fig. 4B). The effects of the
anti-ROR1 mAbs on melanoma cell lines was statistically
significant compared to the non-relevant isotype control mAb
(mouse IgG1 isotype) as well as in comparison to the ROR1
negative cell line T47D (P= 0.05-0.0001).
Silencing of ROR1 in melanoma cells by siRNA
A ROR1 specific siRNA was used to suppress ROR1 expression
in those melanoma cell lines that were most sensitive to the direct
apoptotic effect of the anti-ROR1 mAbs (ESTDAB049, 075, 112,
DFW and A375) as well as the ESTDAB081 melanoma cell line
which was resistant to apoptosis by anti-ROR1 mAbs. Transfec-
tion of melanoma cells induced a marked decrease in the ROR1
gene-expression (RT-PCR) (Fig. 5A). ROR1 was also downreg-
ulated at the protein level (Fig. 5B). Silencing of ROR1 induced
apoptosis of the ROR1 positive melanoma cell lines but not of the
T47D ROR1 negative cell line (Fig. 6). Morphological changes of
the cells typical for apoptosis were noted by light microscopy as
well as loss of adherence to tissue culture plates (data not shown).
cell line T47D (Annexin-V/PI) (C). Western blot for cleaved PARP, caspase 8, 9 and MCL-1 expression in apoptotic ESTDAB049 and ESTDAB112 cells
induced by the anti-ROR1 mAb clone 5F1 (D). (2) cells treated with a non-relevant isotype control mAb (mouse IgG1 isotype). (+) cells treated with
the anti-ROR1 mAb clone 5F1. (S) cells treated with staurosporine.
doi:10.1371/journal.pone.0061167.g002
Figure 3. Anti-ROR1 mAbs in complement dependent cytotoxicity (CDC). Frequency (%) (mean+SEM) of apoptotic/necrotic cells (Annexin-
V+/PI+) induced by 4 anti-ROR1 mAbs with (&) or without (%) human complement using various ESTDAB (A, B), DFW and A375 melanoma cell lines
(C). The T47D cell line did not express ROR1. *P= 0.01; **P= 0.001. P-values refer to comparison with and without complement for the respective
mAbs. NR mAb: non-relevant isotype control mAb (mouse IgG1 isotype), C: Complement.
doi:10.1371/journal.pone.0061167.g003
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Discussion
ROR1 is not only overexpressed in hematologic malignancies,
but also in solid tumors [13,15,30–32]. ROR1 knockdown
prevented growth of primary leukemic cells as well as of breast
cancer cells in vitro and in vivo [13,16,19]. ROR1 was
constitutively phosphorylated in CLL and cell lines of different
origins [16,18]. Current evidence suggests that ROR1 might play
a role as a survival factor for various malignancies and to be an
interesting target for therapy [13,15,17,20].
In the present study we could show that melanoma cell lines
expressed a 130 kDa ROR1 protein, corresponding to the fully
glycosylated isoform [33]. A proportion of melanoma cell lines did
however not express ROR1 on the surface or at least not
detectable by our anti-ROR1 mAbs. This subpopulation might
represent melanoma cells with a low proliferative activity as
ROR1 has been shown to be expressed in less mature cells with a
high rate of cell division [15]. ROR1 was phosphorylated at serine
and tyrosine residues. Transfection of melanoma cells using
ROR1 siRNA, downregulated ROR1, which was proceeded by
apoptosis. Specific anti-ROR1 mAbs induced apoptosis of the
melanoma cells.
Functional characteristics of cellular proteins are related to post-
translational modifications, as glycosylation, forming a unique
functional glycan in the tissue [34–35]. Aberrant glycosylation has
been demonstrated for various proteins in melanoma cells with
functional consequences [27]. The ESTDAB series of melanoma
cell lines showed different glycan patterns which related to clinical
characteristics of the patients from which the cell lines were
derived [21,27–29].
Depending on the glycosylation pattern of an antigen, a
targeting mAb may induce various effects upon binding [36].
The frequency of ROR1 positive cells did not differ markedly
between the various melanoma cell lines, but a significant
variation in the cytotoxic effects of the different anti-ROR1 mAbs
was noted. The ESTDAB081 cell line was resistant to the
apoptotic effect of the anti-ROR1 mAbs, but not to siRNA. These
variations might mirror post-translation modifications of ROR1,
as well as the epitopes recognized by the mAbs in addition to other
factors of importance for drug resistance [36–37]. Gene silencing
of ROR1 induced apoptosis also in mAb resistant cells indicating
that some ROR1 mAbs may not mediate a proper apoptotic
signal.
Figure 4. Cytotoxic effects of anti-ROR1 mAbs in the presence of NK cells (ADCC). Frequency (%) (mean+SEM) of apoptotic/necrotic cells
(Annexin-V+/PI+) induced by 4 anti-ROR1 mAbs and a non-relevant isotype control mAb (mouse IgG1 isotype) in the presence of NK cells at different
target: effector ratios. Target cells: ESTDAB049 (%), 075 ( ), DFW (&), A375 ( ) (A) and ESTDAB081 (%), 094 ( ), 112 (&) melanoma cells and T47D
( ) as a ROR1 negative cell line (B). ADCC of the melanoma cells induced by the anti-ROR1 mAbs compared to the non-relevant isotype control mAb
(mouse IgG1 isotype) as wells as to the T47D cell line was statistically significant (P = 0.05-0.0001).
doi:10.1371/journal.pone.0061167.g004
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The induction of direct apoptosis of melanoma cells is in
agreement with recent findings demonstrating the same phenom-
enon in primary CLL leukemic cells [18,20]. Targeting ROR1 in
CLL with anti-ROR1 mAbs induced rapid dephosphorylation of
ROR1 preceding apoptosis [18,20]. Mechanisms of action for
induction of apoptosis by anti-ROR1 antibodies are not well
understood but pathways as AKT/CREB may be involved
[18,20,31,38]. The A375 melanoma cell line has been shown to
express activated BRAF and mediate a strong BRAF/MEK/ERK
signal [39]. Whether ROR1 activation might be associated with
the BRAF/MEK/ERK signaling pathway or if blocking of ROR1
may mediate cell death through this pathway is not known.
Phosphorylation of serine and tyrosine residues is important for
regulating protein activities including RTKs [40–42]. ROR1 as
well as ErbB2 are both members of the type I RTK subclass,
contributing to the malignant transformation of various human
cancers. High expression of HER1/2, VEGFR2/KRD and
estrogen receptors and their tyrosine phosphorylation in breast
cancer correlated with a poor prognosis [40,43–44]. Our findings,
showing phosphorylation of ROR1 at tyrosine and serine residues
Figure 5. Transfection of melanoma cells (n=6) using ROR1 suppressing siRNA. Downregulation of ROR1 mRNA (RT-PCR) (A).
Downregulation of the ROR1 protein (130 kDa) expression (B). (2) untreated cells, (C) control siRNA treated cells, (+) ROR1 siRNA treated cells.
doi:10.1371/journal.pone.0061167.g005
Figure 6. Apoptosis of melanoma cells treated with siROR1. Dot plot (frequency) of apoptotic/necrotic melanoma cells (Annexin-V+/PI+)
treated with siRNA, control siRNA and untreated. Within each quadrant the frequency of apoptotic cells is shown. Results are presented for the
ESTDAB049, ESTDAB075, A375, ESTDAB112 (sensitive to apoptosis by anti-ROR1 mAbs) and ESTDAB081 (resistant to apoptosis by anti-ROR1 mAbs),
The cell lines T74D cell line was used as a ROR1 negative control.
doi:10.1371/journal.pone.0061167.g006
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in melanoma cell lines is of interest. We have recently shown that
ROR1 is highly phosphorylated in progressive compared to non-
progressive CLL [18]. Furthermore, mouse ROR1 is phosphor-
ylated at the serine position 652 located in the activation segment
of ROR1 both in the human and mouse ROR1 protein and may
be an important site to be triggered by serine/threonine kinases
[45]. It is not clear if phosphorylation of ROR1 at tyrosine [46–
48] or serine [49–50] residues is due to autophosphorylation or
not. Tyrosine and serine phosphorylation might be triggered by
other kinases [51].
Expression of ROR1 has previously been shown in 3 melanoma
cell lines including SK-MEL 2, 5 and 28 and ROR1 was
phosphorylated at tyrosine and serine residues [16]. SiRNA
transfection prevented cell growth only in a low numbers of cells,
probably due to a low expression and phosphorylation of ROR1.
However, a high degree of growth inhibition was observed in the
ROR1 high expressing non-melanoma cell lines NCI-H1993 and
HS746T [16]. These two cell lines had an abnormality in the Met
oncogene inducing activation of Met. ROR1 might have been
phosphorylated by Met as a result of transphosphorylation but a
low degree of autophosphorylation could also be seen [16]. To our
knowledge, there is no report showing aberrant expression of the
Met oncogene in those melanoma cell lines we used. Our data
may support the suggestion that the Met RTK is not the only
RTK to phosphorylate ROR1 [13,15–16,31]. Other modifications
might contribute to the functional properties of ROR1 [52–53].
Furthermore, cells expressing endogenously upregulated ROR1
might be differently activated compared to transfected cells [54–
55].
In summary, we described for the first time the expression of
ROR1 at the mRNA and protein levels in melanoma cells and
could show that targeting melanoma cells by anti-ROR1 mAbs
and ROR1 suppressing RNA induced apoptosis of the cells.
Further studies on the biology of ROR1 in melanoma are
warranted as well as to develop anti-ROR1 targeted therapy.
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